Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

NCT01203631 ·Status: COMPLETED ·Phase: PHASE2

Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease

NCT00102921 ·Status: COMPLETED ·Phase: PHASE2

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

NCT03464097 ·Status: TERMINATED ·Phase: PHASE3

Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

NCT01190410 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease

NCT00573469 ·Status: COMPLETED ·Phase: PHASE2

Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease

NCT00584740 ·Status: TERMINATED ·Phase: PHASE2

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

NCT01316939 ·Status: TERMINATED ·Phase: PHASE3

Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease

NCT00130390 ·Status: TERMINATED ·Phase: PHASE2

A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease

NCT00989573 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease

NCT03992469 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease

NCT00306215 ·Status: COMPLETED ·Phase: PHASE2

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

NCT01470599 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

NCT04877990 ·Status: COMPLETED ·Phase: PHASE2

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

NCT01751152 ·Status: COMPLETED ·Phase: PHASE2

CNI-1493 for Treatment of Moderate to Severe Crohn's Disease

NCT00038766 ·Status: TERMINATED ·Phase: PHASE2

Observational Study of Disease Severity in Participants Diagnosed With Crohn's Disease and Long Term Impact of Treatment Strategies in Participants With Moderate to Severe Crohn's Disease (Protocol P06484)

NCT01218360 ·Status: COMPLETED

Phase IIa Study Evaluating AZD7798 in Crohn's Disease

NCT06450197 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

NCT03440372 ·Status: TERMINATED ·Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801 ·Status: RECRUITING ·Phase: PHASE3

A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

NCT06958536 ·Status: RECRUITING ·Phase: PHASE2

Open-Label Extension Study of GSK1605786A

NCT01318993 ·Status: TERMINATED ·Phase: PHASE3

A Study of TRK-170 for the Treatment of Crohn's Disease

NCT01345799 ·Status: COMPLETED ·Phase: PHASE2

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

NCT03467958 ·Status: TERMINATED ·Phase: PHASE3

NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease

NCT00936585 ·Status: TERMINATED ·Phase: NA

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

NCT05470985 ·Status: TERMINATED ·Phase: PHASE2/PHASE3